| Literature DB >> 16080794 |
John C Licciardone1, Angela K Brimhall, Linda N King.
Abstract
BACKGROUND: Osteopathic manipulative treatment (OMT) is a distinctive modality commonly used by osteopathic physicians to complement their conventional treatment of musculoskeletal disorders. Previous reviews and meta-analyses of spinal manipulation for low back pain have not specifically addressed OMT and generally have focused on spinal manipulation as an alternative to conventional treatment. The purpose of this study was to assess the efficacy of OMT as a complementary treatment for low back pain.Entities:
Mesh:
Year: 2005 PMID: 16080794 PMCID: PMC1208896 DOI: 10.1186/1471-2474-6-43
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Summary of trials.
| 1973–1979 | ... | 1991–1992 | |
| United States | United Kingdom | United Kingdom | |
| University clinic | Hospital outpatient clinic | Ambulatory clinic | |
| 95 | 109 | 30* | |
| OMT vs soft tissue massage and sham manipulation | OMT vs short-wave diathermy | OMT vs sham manipulation | |
| Age, y | |||
| Mean ± SD | OMT, 30.1 ± 8.4 | OMT, 34 ± 14 | Overall age range, 50–60 |
| Sex | |||
| % male | OMT, 59 | OMT, 49 | OMT, 0 |
| Type of low back pain | Referred patients with acute or chronic low back pain | Referred patients with low back pain of greater than 2 months' and less than 12 months' duration | Recruited subjects with chronic low back pain in conjunction with menopausal symptoms |
| Technique | High-velocity, low-amplitude thrust only | Variety of techniques | Low-force techniques |
| No. of treatments | |||
| Mean ± SD | OMT, 4.8 ± 2.7 | 4, per protocol | 10, per protocol |
| Blinded | Blinded | Assessment independent of treatment, blinding not specified | |
| 3 | 6 (3 for each of the two OMT vs control treatment comparisons) | 1 | |
| Dichotomous pain outcomes | Dichotomous pain outcomes | Dichotomous pain outcome | |
| Short-term | First treatment and mean, 20–30 days following randomization | 2 and 4 weeks | ... |
| Intermediate-term | Mean, 41–51 days following randomization | ... | ... |
| Long-term | ... | 12 weeks | 15 weeks |
| 1992–1994 | ... | 2000–2001 | |
| United States | United Kingdom | United States | |
| Health maintenance organization | Hospital orthopedic department | University clinic | |
| 178 | 40 | 91 | |
| Usual care and OMT vs usual care only | OMT vs chemonucleolysis | Usual care and OMT vs usual care and sham manipulation | |
| Age, y | |||
| Mean ± SD | OMT, 28.5 ± 10.6 | Overall, 41.9 ± 10.6 | Usual care and OMT, 49 ± 12 |
| Sex | |||
| % male | OMT, 41 | Overall, 48 | Usual care and OMT, 31 |
| Type of low back pain | Patients with low back pain of 3 or more weeks' and less than 6 months' duration | Recruited patients with low back pain and sciatica; mean duration, 30 and 32 weeks in OMT and chemonucleolysis groups, respectively | Recruited subjects with low back pain of at least 3 months' duration |
| Technique | Variety of techniques, individualized to patient | Variety of techniques, individualized to patient | Variety of techniques, individualized to subject |
| No. of treatments | |||
| Mean ± SD | 8, per protocol | Mean for OMT, 11; range 6–18 | 7, per protocol |
| Blinded | Blinded | Blinded | |
| 1 | 3 | 6 (3 for each of the two OMT vs control treatment comparisons) | |
| Pain scale | Pain scales | Pain scales | |
| Short-term | ... | 2 weeks | 1 month |
| Intermediate-term | 12 weeks | 6 weeks | 3 months |
| Long-term | ... | 12 months | 6 months |
OMT denotes osteopathic manipulative treatment.
*A total of 30 subjects with menopausal symptoms were randomized; however, only 12 subjects had low back pain.
Summary of analyses.*
| Best-case and worst-case scenarios | |
| | |
| 1. Active treatment or placebo control | Best-case and worst-case scenarios |
| 2. No treatment | |
| | |
| 3. United Kingdom | Best-case and worst-case scenarios |
| 4. United States | Best-case and worst-case scenarios |
| | |
| 5. Short-term | Best-case and worst-case scenarios |
| 6. Intermediate-term | 4 possible combinations of contrasts including one control treatment per trial |
| 7. Long-term | 2 possible combinations of contrasts including one control treatment per trial |
*There were insufficient contrasts to perform sensitivity analyses for the no treatment stratified analysis. For the short-term stratified analysis, the median contrast was defined to be that corresponding to the eighth combination when effect sizes for the 16 possible contrast combinations were rank ordered from least to greatest. For the intermediate-and long-term stratified analyses, the median contrasts defaulted to the all-contrasts analyses because there were no repeated measures within these time intervals in any trial. All possible contrast combinations were included in the sensitivity analyses for intermediate-and long-term follow-up because of the limited numbers of combinations for these analyses.
Figure 1Flowchart of trials.
Figure 2Effect size for low back pain. CI denotes confidence interval; OMT, osteopathic manipulative treatment. Overall effect size, -0.30; 95% CI, -0.47 – -0.13; P = .001.
Overall results.
| Median contrasts | ||||||
| Fixed-effects model* | 8 | 318 | 231 | -0.30 | -0.47 – -0.13 | .001 |
| Random-effects model | 8 | 318 | 231 | -0.31 | -0.49 – -0.13 | .001 |
| Best-case scenario | 8 | 293 | 220 | -0.37 | -0.55 – -0.20 | <.001 |
| Worst-case scenario | 8 | 298 | 221 | -0.18 | -0.35 – 0.00 | .046 |
| Median contrasts, one OMT vs control treatment comparison per trial | ||||||
| Gibson [43] active treatment control and Licciardone [46] placebo control | 6 | 237 | 181 | -0.30 | -0.49 – -0.10 | .003 |
| Gibson [43] active treatment control and Licciardone [46] no treatment control | 6 | 247 | 179 | -0.39 | -0.59 – -0.20 | <.001 |
| Gibson [43] placebo control and Licciardone [46] placebo control | 6 | 238 | 187 | -0.26 | -0.45 – -0.06 | .01 |
| Gibson [43] placebo control and Licciardone [46] no treatment control | 6 | 248 | 185 | -0.35 | -0.54 – -0.15 | <.001 |
| Median contrasts, Cleary [47] trial excluded | 7 | 310 | 227 | -0.29 | -0.47 – -0.12 | .001 |
| All contrasts | 20 | 727 | 520 | -0.29 | -0.40 – -0.17 | <.001 |
CI denotes confidence interval; OMT, osteopathic manipulative treatment.
*Test for homogeneity, P = .37.
Stratified results.
| Median contrasts | ||||||
| Fixed-effects model* | 6 | 193 | 142 | -0.26 | -0.48 – -0.05 | .02 |
| Random-effects model | 6 | 193 | 142 | -0.26 | -0.48 – -0.05 | .02 |
| Best-case scenario | 6 | 174 | 132 | -0.34 | -0.57 – -0.11 | .004 |
| Worst-case scenario | 6 | 183 | 134 | -0.07 | -0.29 – 0.16 | .54 |
| Median contrasts, one OMT vs control treatment comparison per trial | ||||||
| Gibson [43] active treatment | 5 | 154 | 109 | -0.33 | -0.58 – -0.08 | .01 |
| Gibson [43] placebo control | 5 | 155 | 115 | -0.26 | -0.51 – -0.02 | .03 |
| Median contrasts, Cleary [47] trial excluded | 5 | 185 | 138 | -0.24 | -0.47 – -0.02 | .03 |
| All contrasts | 16 | 534 | 400 | -0.21 | -0.34 – -0.08 | .002 |
| All contrasts | 4 | 193 | 120 | -0.53 | -0.76 – -0.30 | <.001 |
| Median contrasts | ||||||
| Fixed-effects model* | 4 | 105 | 84 | -0.29 | -0.58 – 0.00 | .050 |
| Random-effects model | 4 | 105 | 84 | -0.30 | -0.63 – 0.02 | .06 |
| Best-case scenario | 4 | 105 | 88 | -0.36 | -0.64 – -0.07 | .01 |
| Worst-case scenario | 4 | 100 | 83 | -0.11 | -0.40 – 0.19 | .48 |
| Median contrasts, one OMT vs control treatment comparison per trial | ||||||
| Gibson [43] active treatment | 3 | 66 | 51 | -0.46 | -0.83 – -0.09 | .02 |
| Gibson [43] placebo control | 3 | 67 | 57 | -0.30 | -0.66 – 0.05 | .10 |
| Median contrasts, Cleary [47] trial excluded | 3 | 97 | 80 | -0.26 | -0.56 – 0.04 | .09 |
| All contrasts | 10 | 294 | 247 | -0.23 | -0.40 – -0.06 | .01 |
| Median contrasts | ||||||
| Fixed-effects model* | 4 | 213 | 147 | -0.31 | -0.52 – -0.10 | .004 |
| Random-effects model | 4 | 213 | 147 | -0.32 | -0.57 – -0.06 | .01 |
| Best-case scenario | 4 | 188 | 132 | -0.38 | -0.61 – -0.16 | .001 |
| Worst-case scenario | 4 | 198 | 138 | -0.22 | -0.44 – 0.00 | .050 |
| Median contrasts, one OMT vs control treatment comparison per trial | ||||||
| Licciardone [46] placebo control | 3 | 171 | 130 | -0.24 | -0.47 – -0.01 | .04 |
| Licciardone [46] no treatment control | 3 | 181 | 128 | -0.36 | -0.59 – -0.14 | .002 |
| All contrasts | 10 | 433 | 273 | -0.33 | -0.48 – -0.18 | <.001 |
| Median contrasts | ||||||
| Fixed-effects model* | 5 | 181 | 130 | -0.28 | -0.51 – -0.06 | .01 |
| Random-effects model | 5 | 181 | 130 | -0.31 | -0.61 – -0.01 | .046 |
| Best-case scenario | 5 | 196 | 142 | -0.41 | -0.62 – -0.19 | <.001 |
| Worst-case scenario | 5 | 181 | 136 | -0.10 | -0.32 – 0.12 | .38 |
| All contrasts | 9 | 357 | 258 | -0.23 | -0.39 – -0.07 | .01 |
| Median (all) contrasts | ||||||
| Fixed-effects model* | 7 | 283 | 209 | -0.33 | -0.51 – -0.15 | <.001 |
| Random-effects model | 7 | 283 | 209 | -0.36 | -0.63 – -0.10 | .01 |
| Median contrasts, one OMT vs control treatment comparison per trial | ||||||
| Gibson [43] active treatment and Licciardone [46] placebo control | 5 | 209 | 161 | -0.31 | -0.52 – -0.10 | .004 |
| Gibson [43] active treatment and Licciardone [46] no treatment control | 5 | 209 | 158 | -0.45 | -0.65 – -0.24 | <.001 |
| Gibson [43] placebo control and Licciardone [46] placebo control | 5 | 209 | 166 | -0.25 | -0.46 – -0.05 | .02 |
| Gibson [43] placebo control and Licciardone [46] no treatment control | 5 | 209 | 163 | -0.39 | -0.59 – -0.18 | <.001 |
| Median (all) contrasts | ||||||
| Fixed-effects model* | 4 | 87 | 53 | -0.40 | -0.74 – -0.05 | .03 |
| Random-effects model | 4 | 87 | 53 | -0.41 | -0.82 – -0.01 | .046 |
| Median contrasts, one OMT vs control treatment comparison per trial | ||||||
| Licciardone [46] placebo control | 3 | 55 | 38 | -0.23 | -0.65 – 0.19 | .28 |
| Licciardone [46] no treatment control | 3 | 55 | 34 | -0.64 | -1.08 – -0.20 | .01 |
| Median contrasts, Cleary [47] trial excluded | 3 | 79 | 49 | -0.36 | -0.72 – 0.01 | .054 |
CI denotes confidence interval; OMT, osteopathic manipulative treatment.
*Tests of homogeneity, P = .45 and P = .06 for active treatment or placebo control, and no treatment control groups, respectively; P = .32 and P = .26 for trials in the United Kingdom and the United States, respectively; and P = .14, P = .06, and P = .28 for short-term, intermediate-term, and long-term follow-up, respectively.
Figure 3Summary of meta-analysis results. A denotes all-contrasts model; B, best-case scenario model; C, Cleary [47] trial excluded model; M, median contrasts model; NT, no treatment control; OMT, osteopathic manipulative treatment; W, worst-case scenario model. 1, 2, 3, and 4 indicate alternative models restricted to one OMT vs control treatment comparison per trial. A diamond indicates the inclusion of the relevant contrast or observation of the stated result. Sensitivity analyses are shaded in gray. Results are presented for each of the 43 analyses, including the overall meta-analysis, seven stratified meta-analyses, and 35 sensitivity analyses.